

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1617SXK

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/CAplus enhanced with utility model patents from China
NEWS 6 JUL 16 CAplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/CAplus patent coverage enhanced
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 BEILSTEIN updated with new compounds
NEWS 12 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 13 AUG 13 CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14 AUG 20 CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16 AUG 27 USPATOLD now available on STN
NEWS 17 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19 SEP 13 FORIS renamed to SOFIS
NEWS 20 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 21 SEP 17 CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22 SEP 17 CAplus coverage extended to include traditional medicine patents

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:56:26 ON 21 SEP 2007

=> file caplus medline embase biosis

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

0.21

TOTAL

SESSION

0.21

FILE 'CAPLUS' ENTERED AT 15:56:48 ON 21 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 15:56:48 ON 21 SEP 2007

FILE 'EMBASE' ENTERED AT 15:56:48 ON 21 SEP 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:56:48 ON 21 SEP 2007

Copyright (c) 2007 The Thomson Corporation

=> s galantamine

L1 4488 GALANTAMINE

=> s attention deficit disorder

L2 32239 ATTENTION DEFICIT DISORDER

=> s L1 and L2

L3 74 L1 AND L2

=> dup rem L3

PROCESSING COMPLETED FOR L3

L4 71 DUP REM L3 (3 DUPLICATES REMOVED)

=> s L4 and (AY<2004 or PY<2004 or PRY<2004)

'2004' NOT A VALID FIELD CODE

'2004' NOT A VALID FIELD CODE

2 FILES SEARCHED...

'2004' NOT A VALID FIELD CODE

L5 19 L4 AND (AY<2004 OR PY<2004 OR PRY<2004)

=> d 1-19 L5 ibib abs

L5 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1004355 CAPLUS

DOCUMENT NUMBER: 143:279430

TITLE: Use of D4 and 5-HT2a antagonists, inverse agonists or partial agonists

INVENTOR(S): Buntinx, Erik

PATENT ASSIGNEE(S): Belg.

SOURCE: U.S. Pat. Appl. Publ., 126 pp., Cont.-in-part of U.S. Ser. No. 803,793.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|--------------|
| US 2005203130 | A1 | 20050915 | US 2004-984683 | 20041109 <-- |
| US 2005119253 | A1 | 20050602 | US 2003-725965 | 20031202 <-- |
| US 2005119248 | A1 | 20050602 | US 2004-752423 | 20040106 <-- |
| US 2005119249 | A1 | 20050602 | US 2004-803793 | 20040318 <-- |

| | | | | |
|--|----|----------|-----------------|-----------------|
| EP 1541197 | A1 | 20050615 | EP 2004-25035 | 20041021 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| CA 2547639 | A1 | 20050616 | CA 2004-2547639 | 20041202 <-- |
| WO 2005053796 | A1 | 20050616 | WO 2004-BE172 | 20041202 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML,
MR, NE, SN, TD, TG | | | | |
| EP 1708790 | A1 | 20061011 | EP 2004-801138 | 20041202 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
BA, HR, IS, YU | | | | |
| JP 2007513095 | T | 20070524 | JP 2006-541759 | 20041202 <-- |
| US 2007078162 | A1 | 20070405 | US 2006-580962 | 20060531 <-- |
| PRIORITY APPLN. INFO.: | | | US 2003-725965 | A2 20031202 <-- |
| | | | EP 2004-447001 | A 20040105 |
| | | | US 2004-752423 | A2 20040106 |
| | | | US 2004-803793 | A2 20040318 |
| | | | EP 2004-25035 | A 20041021 |
| | | | CA 2003-2451798 | A 20031202 <-- |
| | | | EP 2003-447279 | A 20031202 <-- |
| | | | CA 2004-2461248 | A 20040318 |
| | | | EP 2004-447066 | A 20040318 |
| | | | JP 2004-349085 | A 20041104 |
| | | | US 2004-984683 | A 20041109 |
| | | | CA 2004-2487529 | A 20041115 |
| | | | WO 2004-BE172 | W 20041202 |

AB The present invention relates to the use of compds. and compns. of compds. having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperesthesia-dissociative phenomena-etc.). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compds. having D4 antagonistic, partial agonistic or inverse agonistic activity and (ii) compds. having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and (iii) any known medicinal compound and compns. of said compds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biol. compound or in two different chemical and/or biol. compds.

L5 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:516281 CAPLUS
 DOCUMENT NUMBER: 143:38421
 TITLE: Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
 INVENTOR(S): Buntinx, Erik
 PATENT ASSIGNEE(S): B&B Beheer N. V., Belg.
 SOURCE: Eur. Pat. Appl., 145 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

| | | | | |
|--|----|----------|-----------------|-----------------|
| EP 1541197 | A1 | 20050615 | EP 2004-25035 | 20041021 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| EP 1547650 | A1 | 20050629 | EP 2003-447279 | 20031202 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| EP 1576985 | A1 | 20050921 | EP 2004-447066 | 20040318 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| JP 2005194263 | A | 20050721 | JP 2004-349085 | 20041104 <-- |
| US 2005203130 | A1 | 20050915 | US 2004-984683 | 20041109 <-- |
| CA 2487529 | A1 | 20050602 | CA 2004-2487529 | 20041115 <-- |
| CA 2547639 | A1 | 20050616 | CA 2004-2547639 | 20041202 <-- |
| WO 2005053796 | A1 | 20050616 | WO 2004-BE172 | 20041202 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| EP 1708790 | A1 | 20061011 | EP 2004-801138 | 20041202 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
BA, HR, IS, YU | | | | |
| JP 2007513095 | T | 20070524 | JP 2006-541759 | 20041202 <-- |
| US 2007078162 | A1 | 20070405 | US 2006-580962 | 20060531 <-- |
| PRIORITY APPLN. INFO.: | | | EP 2003-447279 | A 20031202 <-- |
| | | | EP 2004-447001 | A 20040105 |
| | | | EP 2004-447066 | A 20040318 |
| | | | CA 2003-2451798 | A 20031202 <-- |
| | | | US 2003-725965 | A2 20031202 <-- |
| | | | US 2004-752423 | A2 20040106 |
| | | | CA 2004-2461248 | A 20040318 |
| | | | US 2004-803793 | A2 20040318 |
| | | | EP 2004-25035 | A 20041021 |
| | | | JP 2004-349085 | A 20041104 |
| | | | US 2004-984683 | A 20041109 |
| | | | CA 2004-2487529 | A 20041115 |
| | | | WO 2004-BE172 | W 20041202 |

AB The present invention relates to the use of compds. and compns. of compds. having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperesthesia-dissociative phenomena-etc.). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compds. having D4 antagonistic, partial agonistic or inverse agonistic activity and (ii) compds. having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and (iii) any known medicinal compound and compns. of said compds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biol. compound or in two different chemical and/or biol. compds.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:395100 CAPLUS
 DOCUMENT NUMBER: 142:435801

TITLE: Pharmaceuticals comprising a monoamine
 neurotransmitter re-uptake inhibitor and an
 acetylcholinesterase inhibitor
 INVENTOR(S): Friedl, Thomas; Mierau, Joachim; Raschig, Andreas;
 Reess, Juergen; Scheel-Krueger, Joergen
 PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany;
 Boehringer Ingelheim Pharma GmbH & Co. Kg; Neurosearch
 A/S
 SOURCE: PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|------------------|----------------|
| WO 2005039580 | A1 | 20050506 | WO 2004-EP11093 | 20041005 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| AU 2004283425 | A1 | 20050506 | AU 2004-283425 | 20041005 <-- |
| CA 2542442 | A1 | 20050506 | CA 2004-2542442 | 20041005 <-- |
| EP 1675591 | A1 | 20060705 | EP 2004-790120 | 20041005 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| CN 1867333 | A | 20061122 | CN 2004-80030623 | 20041005 <-- |
| JP 2007508336 | T | 20070405 | JP 2006-534638 | 20041005 <-- |
| US 2005154009 | A1 | 20050714 | US 2004-965994 | 20041015 <-- |
| MX 2006PA03762 | A | 20060614 | MX 2006-PA3762 | 20060404 <-- |
| IN 2006DN02712 | A | 20070810 | IN 2006-DN2712 | 20060515 <-- |
| PRIORITY APPLN. INFO.: | | | EP 2003-23635 | A 20031016 <-- |
| | | | EP 2004-5819 | A 20040311 |
| | | | DE 2003-10353832 | A 20031118 <-- |
| | | | WO 2004-EP11093 | W 20041005 |

OTHER SOURCE(S): MARPAT 142:435801
 AB The invention relates to a pharmaceutical composition comprising a monoamine
 neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted
 tropane moiety, or a tautomer, a salt, solvate, or a derivative thereof, and
 at least one acetylcholinesterase inhibitor and a carrier or excipient,
 and optionally one or more other therapeutic ingredients. Thus, granules
 contained a monoamine neurotransmitter re-uptake inhibitor 1.585,
 rivastigmine hydrogen tartrate 9.597, microcryst. cellulose 66.472,
 dibasic calcium phosphate 66.471, Hypromellose 2.750, crosslinked CM-
 cellulose sodium 2.000, colloidal silica 0.375, and Mg stearate 0.750
 mg/capsule.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:414630 CAPLUS
 DOCUMENT NUMBER: 140:412338
 TITLE: Once a day galantamine pharmaceutical
 compositions and methods of use
 INVENTOR(S): Cantillion, Marc; Hsu, Ann; Han, Chien-Hsuan
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 9 pp.

CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|--------------|
| US 2004097484 | A1 | 20040520 | US 2002-293942 | 20021114 <-- |
| PRIORITY APPLN. INFO.: | | | US 2002-293942 | 20021114 <-- |

AB Disclosed are once a day pharmaceutical compns. containing acetylcholinesterase inhibitors, including those with nicotinic receptor modulation such as galantamine or a pharmaceutically acceptable salt thereof. Also disclosed is the use of such compns., for example, for treating or preventing cognitive or other CNS performance impairment in a mammal, such as primary or secondary memory impairment, toxic, secondary to medical or psychiatric, Alzheimer's, vascular and other dementias, mild cognitive impairments, and other cognitive impairments, such as attention deficit disorder, fibromyalgia, chronic fatigue syndrome, PTSD and Down's syndrome. This includes behavioral efficacy, as anxiety depression apathy and agitation, in addition to neurophysiol. and functional outcomes including a decrease in care givers distress. A prolonged release tablet contained galantamine HBr 2.16, xanthan gum 19.35, locust bean gum 58.06, microcryst. cellulose (Avicel PH-101) 13.51, lactose monohydrate (Fast-Flo 316) 6.76, and magnesium stearate 0.16%.

L5 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:80456 CAPLUS
 DOCUMENT NUMBER: 140:122818
 TITLE: Cholinergic therapy for individuals with learning disabilities
 INVENTOR(S): Heller, James H.; Kishnani, Priya; Worley, Gordon
 PATENT ASSIGNEE(S): Duke University, USA; Spiridigliozi, Gail A.; Doraiswamy, Murali P.; Krishnan, Ranga R.
 SOURCE: PCT Int. Appl., 27 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------------|
| WO 2004009026 | A2 | 20040129 | WO 2003-US22746 | 20030722 <-- |
| WO 2004009026 | A3 | 20040715 | | |
| WO 2004009026 | A8 | 20050331 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003256644 | A1 | 20040209 | AU 2003-256644 | 20030722 <-- |
| PRIORITY APPLN. INFO.: | | | US 2002-397123P | P 20020722 <-- |
| | | | WO 2003-US22746 | W 20030722 <-- |

AB Cholinergic agents are used to improve specific learning deficits and language function in individuals of normal intelligence. Psychosocial deficits including a pragmatics impairment, reading deficits, a problem solving impairment, an information processing impairment, an adaptive function impairment, social skills impairment, attention impairment, a

mood impairment and employment skills impairment, can also be treated in this manner. The cholinergic treatments can be combined with more traditional educational, psychol., and behavioral therapies for enhanced therapeutic benefit.

L5 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:319255 CAPLUS
 DOCUMENT NUMBER: 138:343854
 TITLE: Buccal sprays or capsules containing drugs for treating disorders of the central nervous system
 INVENTOR(S): Dugger, Harry A., III
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 537,118.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 19
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|--------------|
| US 2003077227 | A1 | 20030424 | US 2002-230060 | 20020829 <-- |
| WO 9916417 | A1 | 19990408 | WO 1997-US17899 | 19971001 <-- |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,
UZ, VN, ZW | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
GN, ML, MR, NE, SN, TD, TG | | | | |
| EP 1029536 | A1 | 20000823 | EP 2000-109347 | 19971001 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |
| EP 1036561 | A1 | 20000920 | EP 2000-109357 | 19971001 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |
| CA 2497262 | A1 | 20040429 | CA 2003-2497262 | 20030827 <-- |
| WO 2004035021 | A2 | 20040429 | WO 2003-US26847 | 20030827 <-- |
| WO 2004035021 | A3 | 20041111 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003298564 | A1 | 20040504 | AU 2003-298564 | 20030827 <-- |
| EP 1539106 | A2 | 20050615 | EP 2003-796314 | 20030827 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| JP 2006505569 | T | 20060216 | JP 2004-545251 | 20030827 <-- |
| US 2004141923 | A1 | 20040722 | US 2003-671720 | 20030929 <-- |
| US 2004265239 | A1 | 20041230 | US 2003-671715 | 20030929 <-- |
| US 2005163719 | A1 | 20050728 | US 2003-671709 | 20030929 <-- |
| US 2004120895 | A1 | 20040624 | US 2003-726585 | 20031204 <-- |
| US 6977070 | B2 | 20051220 | | |
| US 2005002867 | A1 | 20050106 | US 2004-834815 | 20040427 <-- |
| US 2006159624 | A1 | 20060720 | US 2006-384444 | 20060321 <-- |
| US 2006171896 | A1 | 20060803 | US 2006-391297 | 20060329 <-- |
| US 2006222597 | A1 | 20061005 | US 2006-442137 | 20060530 <-- |

| | | | | |
|------------------------|----|----------|-----------------|-----------------|
| US 2006216240 | A1 | 20060928 | US 2006-443253 | 20060531 <-- |
| US 2006216241 | A1 | 20060928 | US 2006-443254 | 20060531 <-- |
| PRIORITY APPLN. INFO.: | | | WO 1997-US17899 | A2 19971001 <-- |
| | | | US 2000-537118 | A2 20000329 <-- |
| | | | EP 1997-911621 | A3 19971001 <-- |
| | | | US 2002-230060 | A 20020829 <-- |
| | | | WO 2003-US26847 | W 20030827 <-- |
| | | | US 2003-671709 | A3 20030929 <-- |
| | | | US 2003-671715 | A3 20030929 <-- |
| | | | US 2003-671720 | A3 20030929 <-- |
| | | | US 2004-834815 | A3 20040427 |

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation A: aqueous polar solvent, active compound, and optional flavoring agent; formulation B: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation C: non-polar solvent, active compound, and optional flavoring agent; and formulation D: non-polar solvent, active compound, optional flavoring agent, and propellant. Thus, a lingual spray contained sumatriptan succinate 10-15, EtOH 10-20, propylene glycol 10-15, PEG 35-40, water 10-15, and flavors 2-3%.

L5 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:133030 CAPLUS
 DOCUMENT NUMBER: 138:163577
 TITLE: Improving neurological functions
 INVENTOR(S): Chez, Michael G.
 PATENT ASSIGNEE(S): Carn-Aware LLC, USA
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--|----------|-----------------|----------------|
| WO 2003013514 | A1 | 20030220 | WO 2002-US22341 | 20020715 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 2002355388 | A1 | 20030224 | AU 2002-355388 | 20020715 <-- |
| US 2006052428 | A1 | 20060309 | US 2005-486077 | 20050210 <-- |
| PRIORITY APPLN. INFO.: | | | US 2001-310710P | P 20010808 <-- |
| | | | US 2001-325136P | P 20010927 <-- |
| | | | WO 2002-US22341 | W 20020715 <-- |

OTHER SOURCE(S): MARPAT 138:163577

AB The present invention relates to materials and methods for treating neurol. diseases and disorders including but not limited to epilepsy and autism, as well as general cognitive problems. Preferred compds. include carnosine and homocarnosine and N-acetyl, methylated (anserine, ophididine), decarboxylated (carcinine) and tauryl derivs. of carnosine and homocarnosine.


REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:314758 CAPLUS
 DOCUMENT NUMBER: 136:319416
 TITLE: Combination of acetylcholinesterase inhibitors and GABAA inverse agonists for the treatment of cognitive disorders
 INVENTOR(S): Villalobos, Anabella; Cassella, James Vincent;
 Rajachandran, Lavanya
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA; Neurogen Corporation
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-----------------|
| WO 2002032412 | A2 | 20020425 | WO 2001-IB1934 | 20011015 <-- |
| WO 2002032412 | A3 | 20030320 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2002151591 | A1 | 20021017 | US 2001-976347 | 20011012 <-- |
| CA 2426120 | A1 | 20020425 | CA 2001-2426120 | 20011015 <-- |
| AU 2001094117 | A5 | 20020429 | AU 2001-94117 | 20011015 <-- |
| EP 1328294 | A2 | 20030723 | EP 2001-974604 | 20011015 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| HU 200302476 | A2 | 20031128 | HU 2003-2476 | 20011015 <-- |
| JP 2004511512 | T | 20040415 | JP 2002-535650 | 20011015 <-- |
| NZ 525103 | A | 20041224 | NZ 2001-525103 | 20011015 <-- |
| ZA 2003002918 | A | 20040413 | ZA 2003-2918 | 20030411 <-- |
| US 2005009861 | A1 | 20050113 | US 2004-912993 | 20040806 <-- |
| PRIORITY APPLN. INFO.: | | | US 2000-241145P | P 20001017 <-- |
| | | | US 2001-976347 | A1 20011012 <-- |
| | | | WO 2001-IB1934 | W 20011015 <-- |

OTHER SOURCE(S): MARPAT 136:319416
 GI



AB This invention provides a composition for treating a cognitive disorder, which comprises an acetylcholinesterase, and a GABAA inverse agonist selected from a compound (I, where X = e.g., H, halo, Ph, naphthyl, pyridinyl; Y = e.g., C1-8 alkyl, carbocycle). Thus, aricept and a GABAA inverse agonist (e.g., N-benzyl-6-ethoxy-4-oxo-1,4-tetrahydro-1,5-naphthyridine-3-carboxamide), when coadministered, interact to attenuate scopolamine-induced deficits in the spatial water maze.

L5 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:564797 CAPLUS
 DOCUMENT NUMBER: 135:117204
 TITLE: Computer-based cognitive function testing for measuring pharmaceutical-related cognitive impairment
 INVENTOR(S): Erlanger, David; Kaplan, Darin; Shchogolev, Vladislav;
 PATENT ASSIGNEE(S): Theodoracopulos, Alexis; Yee, Philip; Comrie, McDonald Panmedix Incorporated, USA
 SOURCE: PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------------|
| WO 2001054650 | A2 | 20010802 | WO 2001-US2187 | 20010123 <-- |
| W: AU, CA, CH, CZ, IL, JP, KR, SG | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | |
| AU 2001029717 | A5 | 20010807 | AU 2001-29717 | 20010123 <-- |
| PRIORITY APPLN. INFO.: | | | US 2000-494476 | A 20000131 <-- |
| | | | WO 2001-US2187 | W 20010123 <-- |

AB The invention generally involves using a computer to show a patient taking a pharmaceutical product a series of cognitive dysfunction tests, receiving the patient's test responses, and analyzing the responses to assess cognitive dysfunction in the patient, whereby a conclusion can be obtained regarding whether symptoms of cognitive dysfunction probably exist or are absent in the patient, and the drug's likely causal effect on cognitive dysfunction. The invention enables the comparison of multiple test results over time.

L5 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:456886 CAPLUS
 DOCUMENT NUMBER: 133:94514
 TITLE: Controlled release galantamine compositions for treating Alzheimer's dementia
 INVENTOR(S): McGee, John Paul; Gilis, Paul Marie Victor; De Weer, Marc Maurice Germain; De Conde, Valentin Florent Victor; De Brujin, Herman Johannes Catherina; Van Dycke, Frederic Anne Rodolf
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|--------------|
| WO 2000038686 | A1 | 20000706 | WO 1999-EP10257 | 19991220 <-- |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2358062 | A1 | 20000706 | CA 1999-2358062 | 19991220 <-- |
| CA 2358062 | C | 20061219 | | |
| BR 9916835 | A | 20010925 | BR 1999-16835 | 19991220 <-- |

| | | | | |
|--|----|----------|-------------------|--------------|
| EP 1140105 | A1 | 20011010 | EP 1999-965527 | 19991220 <-- |
| EP 1140105 | B1 | 20031022 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |
| TR 200101822 | T2 | 20011121 | TR 2001-200101822 | 19991220 <-- |
| HU 200104778 | A2 | 20020429 | HU 2001-4778 | 19991220 <-- |
| JP 2002533396 | T | 20021008 | JP 2000-590639 | 19991220 <-- |
| EE 200100319 | A | 20021015 | EE 2001-319 | 19991220 <-- |
| NZ 511643 | A | 20030725 | NZ 1999-511643 | 19991220 <-- |
| AT 252386 | T | 20031115 | AT 1999-965527 | 19991220 <-- |
| PT 1140105 | T | 20040331 | PT 1999-965527 | 19991220 <-- |
| ES 2211215 | T3 | 20040701 | ES 1999-965527 | 19991220 <-- |
| AU 775914 | B2 | 20040819 | AU 2000-21006 | 19991220 <-- |
| TW 262079 | B | 20060921 | TW 1999-88122698 | 19991223 <-- |
| IN 2001MN00558 | A | 20050304 | IN 2001-MN558 | 20010515 <-- |
| BG 105564 | A | 20020131 | BG 2001-105564 | 20010605 <-- |
| NO 2001002857 | A | 20010608 | NO 2001-2857 | 20010608 <-- |
| HR 2001000463 | A1 | 20020831 | HR 2001-463 | 20010619 <-- |
| ZA 2001005132 | A | 20020621 | ZA 2001-5132 | 20010621 <-- |
| MX 2001PA06529 | A | 20010910 | MX 2001-PA6529 | 20010622 <-- |
| US 7160559 | B1 | 20070109 | US 2001-868991 | 20010726 <-- |
| US 2006062856 | A1 | 20060323 | US 2005-262668 | 20051031 <-- |
| US 2006093671 | A1 | 20060504 | US 2005-304128 | 20051215 <-- |
| PRIORITY APPLN. INFO.: | | | | |
| EP 1998-204447 A 19981224 <-- | | | | |
| WO 1999-EP10257 W 19991220 <-- | | | | |
| US 2001-868991 A1 20010726 <-- | | | | |

AB The present invention is concerned with controlled release compns. for oral administration comprising galantamine; and with processes of preparing such controlled release compns. A method of treating Alzheimer's dementia and related dementias comprises administering the controlled release galantamine formulation.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:130564 CAPLUS
 DOCUMENT NUMBER: 130:187195
 TITLE: Use of cholinesterase inhibitors for treating attention deficit disorders
 INVENTOR(S): Snorrason, Ernir; Murray, James Robert
 PATENT ASSIGNEE(S): Shire International Licensing B.V., Neth.
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|--------------|
| WO 9907359 | A1 | 19990218 | WO 1998-GB2378 | 19980807 <-- |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2300405 | A1 | 19990218 | CA 1998-2300405 | 19980807 <-- |
| AU 9887367 | A | 19990301 | AU 1998-87367 | 19980807 <-- |
| ZA 9807140 | A | 19990309 | ZA 1998-7140 | 19980807 <-- |
| EP 1001761 | A1 | 20000524 | EP 1998-938759 | 19980807 <-- |
| EP 1001761 | B1 | 20040728 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |

IE, FI
 JP 2001513496 T 20010904 JP 2000-506951 19980807 <--
 AT 271865 T 20040815 AT 1998-938759 19980807 <--
 ES 2224421 T3 20050301 ES 1998-938759 19980807 <--
 TW 577742 B 20040301 TW 1998-87113353 19980813 <--
 PRIORITY APPLN. INFO.: GB 1997-16879 A 19970808 <--
 WO 1998-GB2378 W 19980807 <--

OTHER SOURCE(S): MARPAT 130:187195

AB The invention provides the use of cholinesterase inhibitors, particularly acetylcholinesterase inhibitors such as galanthamine, in the manufacture of a medicament for combating attention deficit disorders.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 19 MEDLINE on STN

ACCESSION NUMBER: 2003133599 MEDLINE

DOCUMENT NUMBER: PubMed ID: 12647432

TITLE: [Acetylcholinesterase inhibitors--beyond Alzheimer's disease].

Inhibitory acetylocholinesterazy--nie tylko w chorobie Alzheimera.

AUTHOR: Kloszewska Iwona

CORPORATE SOURCE: I Klinika Psychiatryczna Katedry Psychiatrii AM w Lodzi.

SOURCE: Psychiatria polska, (2002 Nov-Dec) Vol. 36, No. 6

Suppl, pp. 133-41. Ref: 37

Journal code: 0103314. ISSN: 0033-2674.

Poland

DOCUMENT TYPE: (ENGLISH ABSTRACT)

Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LANGUAGE: Polish

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200306

ENTRY DATE: Entered STN: 22 Mar 2003

Last Updated on STN: 6 Jun 2003

Entered Medline: 5 Jun 2003

AB Based on a literature review, the application of Acetylcholinesterase inhibitors, IAChE (donepezil, rivastigmine, galantamine) in the treatment of various illnesses which have cholinergic system disability and dementia in their course--(dementia with Lewy bodies, vascular dementia, Parkinson's disease, Multiple Sclerosis, Down Syndrome), delirium symptoms (e.g. Korsakoff psychosis), hyperkinesis, attention and memory disorders--is presented. Promising results in the treatment of late dyskinésias, in schizophrenia with impaired cognitive function, as well as in the additional treatment of various psychotic states are noted. It should be stressed that in Poland, the IAChE have been approved only in the treatment of slight to moderate dementia in the course of Alzheimer's disease.

L5 ANSWER 13 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004151029 EMBASE

TITLE: 2003 Psychotropic Dosing and Monitoring Guidelines.

AUTHOR: DeBattista C.; Schatzberg A.F.; Norris K.T.

SOURCE: Primary Psychiatry, (2003) Vol. 10, No. 7, pp. 80-84+87-96.

Refs: 75

ISSN: 1082-6319 CODEN: PPRSC5

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 032 Psychiatry

037 Drug Literature Index

038 Adverse Reactions Titles

LANGUAGE: English

ENTRY DATE: Entered STN: 22 Apr 2004
Last Updated on STN: 22 Apr 2004

L5 ANSWER 14 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003041424 EMBASE

TITLE: XIVth World Congress of Pharmacology, San Francisco, CA, USA July 7-12, 2002 new drugs for the treatment of central nervous system disorders.

AUTHOR: Scriabine A.

CORPORATE SOURCE: A. Scriabine, Dept. of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, United States. alexander.scriabine@snet.net

SOURCE: CNS Drug Reviews, (2002) Vol. 8, No. 4, pp. 427-437. .
ISSN: 1080-563X CODEN: CDREFB

COUNTRY: United States

DOCUMENT TYPE: Journal; Conference Article

FILE SEGMENT: 008 Neurology and Neurosurgery
032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

ENTRY DATE: Entered STN: 7 Feb 2003
Last Updated on STN: 7 Feb 2003

L5 ANSWER 15 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002420945 EMBASE

TITLE: Alzheimer's disease and the basal forebrain cholinergic system: Relations to β -amyloid peptides, cognition, and treatment strategies.

AUTHOR: Auld D.S.; Kornecook T.J.; Bastianetto S.; Quirion R.

CORPORATE SOURCE: R. Quirion, Douglas Hospital Research Centre, 6875 Blvd. Lasalle, Verdun, Que. H4H 1R3, Canada.
quirrem@douglas.mcgill.ca

SOURCE: Progress in Neurobiology, (2002) Vol. 68, No. 3, pp. 209-245. .
Refs: 504
ISSN: 0301-0082 CODEN: PGNBA5
S 0301-0082(02)00079-5

PUBLISHER IDENT.: United Kingdom

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 008 Neurology and Neurosurgery
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 12 Dec 2002
Last Updated on STN: 12 Dec 2002

AB Alzheimer's disease (AD) is the most common form of degenerative dementia and is characterized by progressive impairment in cognitive function during mid- to late-adult life. Brains from AD patients show several distinct neuropathological features, including extracellular β -amyloid-containing plaques, intracellular neurofibrillary tangles composed of abnormally phosphorylated τ , and degeneration of cholinergic neurons of the basal forebrain. In this review, we will present evidence implicating involvement of the basal forebrain cholinergic system in AD pathogenesis and its accompanying cognitive deficits. We will initially discuss recent results indicating a link between cholinergic mechanisms and the pathogenic events that characterize AD, notably amyloid- β peptides. Following this, animal models of dementia will be discussed in light of the relationship between basal forebrain cholinergic hypofunction and cognitive impairments in AD.

Finally, past, present, and future treatment strategies aimed at alleviating the cognitive symptomatology of AD by improving basal forebrain cholinergic function will be addressed. .COPYRGT. 2002 Elsevier Science Ltd. All rights reserved.

L5 ANSWER 16 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002200626 EMBASE

TITLE: Down syndrome and dementia.

AUTHOR: Pary R.J.

CORPORATE SOURCE: Dr. R.J. Pary, Department of Psychiatry, Southern Illinois University, School of Medicine, PO Box 19642, Springfield, IL 62794-9642, United States

SOURCE: Mental Health Aspects of Developmental Disabilities, (2002) Vol. 5, No. 2, pp. 57-63. .

Refs: 35

ISSN: 1057-3291 CODEN: MHADFR

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT:

| | |
|-----|---|
| 008 | Neurology and Neurosurgery |
| 038 | Adverse Reactions Titles |
| 032 | Psychiatry |
| 037 | Drug Literature Index |
| 030 | Pharmacology |
| 022 | Human Genetics |
| 036 | Health Policy, Economics and Management |

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20 Jun 2002
Last Updated on STN: 20 Jun 2002

AB This article reviews the advances in the evaluation and management of dementia in persons with Down syndrome. It is not inevitable that all older persons with Down syndrome will develop dementia. One of the major changes has been in the evaluation of dementia-like syndrome. This article will review laboratory tests as well as dementia scales, neuropsychological batteries and standardized mental status evaluations. Pharmacological management is also discussed. Lastly, there is a need for expert consensus on clinical guidelines for the evaluation and management of dementia in persons with Down syndrome.

L5 ANSWER 17 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001434139 EMBASE

TITLE: NICE: Faster access to modern treatments? Analysis of guidance on health technologies.

AUTHOR: Raftery J.

CORPORATE SOURCE: Prof. J. Raftery, Health Services Management Centre, School of Public Policy, University of Birmingham, Birmingham B15 2RT, United Kingdom. J.P.Raftery@bham.ac.uk

SOURCE: British Medical Journal, (1 Dec 2001) Vol. 323, No. 7324, pp. 1300-1303. .

Refs: 12

ISSN: 0959-8146 CODEN: BMJOAE

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT:

| | |
|-----|---|
| 017 | Public Health, Social Medicine and Epidemiology |
| 036 | Health Policy, Economics and Management |
| 037 | Drug Literature Index |

LANGUAGE: English

ENTRY DATE: Entered STN: 3 Jan 2002
Last Updated on STN: 3 Jan 2002

L5 ANSWER 18 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001395243 EMBASE

TITLE: A NICE job and somebody's got to do it.
 SOURCE: Pharmaceutical Journal, (27 Oct 2001) Vol. 267, No. 7171,
 pp. 591-592.
 ISSN: 0031-6873 CODEN: PHJOAV
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Note
 FILE SEGMENT:
 006 Internal Medicine
 010 Obstetrics and Gynecology
 016 Cancer
 017 Public Health, Social Medicine and Epidemiology
 036 Health Policy, Economics and Management
 037 Drug Literature Index
 LANGUAGE: English
 ENTRY DATE: Entered STN: 26 Nov 2001
 Last Updated on STN: 26 Nov 2001

L5 ANSWER 19 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
 ACCESSION NUMBER: 2000356700 EMBASE
 TITLE: Therapeutic agents for attention deficit disorders.
 AUTHOR: Howard H.R.
 CORPORATE SOURCE: H.R. Howard, Department of Neurosciences, Pfizer Global Research Division, Pfizer Inc., Groton, CT 06340, United States
 SOURCE: Expert Opinion on Therapeutic Patents, (2000) Vol. 10, No. 10, pp. 1549-1559.
 Refs: 38
 ISSN: 1354-3776 CODEN: EOTPEG
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; General Review
 FILE SEGMENT:
 007 Pediatrics and Pediatric Surgery
 030 Pharmacology
 032 Psychiatry
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 26 Oct 2000
 Last Updated on STN: 26 Oct 2000

AB: Attention deficit hyperactivity disorder (ADHD) is a syndrome that affects young children, manifesting itself through inappropriate behaviours and learning difficulties and persisting in many instances into adulthood. Treatment with stimulants, such as methylphenidate, is often sufficient but carries with it some risk for the emergence of unwanted side effects that can influence compliance, particularly with children. Newer agents and novel mechanisms for achieving control of the symptoms associated with ADHD are proposed in recent patents and applications and are presented in this review.

=> logoff
 ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| FULL ESTIMATED COST | 75.82 | 76.03 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -8.58 | -8.58 |

STN INTERNATIONAL LOGOFF AT 16:02:56 ON 21 SEP 2007